Skip to content
Mushroom Retreats
Not yet recruitingPhase 1NCT07833761

ADEPT Psilocybin-Assisted Therapy With DBT for Borderline Personality Disorder

ADEPT is an open-label proof-of-concept study evaluating the safety and tolerability of psilocybin-assisted therapy in conjunction with Dialectical Behavior Therapy for participants with borderline personality disorder. (The sponsor's summary, shortened.)

Eligibility and contacts on ClinicalTrials.gov

The registry record

Status
Not yet recruiting
Phase
Phase 1
Conditions
Borderline Personality Disorder; Borderline Personality Pathology; Depressive Symptoms; Emotion Dysregulation; Suicidal Ideation
Intervention
Psilocybin; Psilocybin-Assisted Therapy With Dialectical Behavior Therapy
Sponsor
University of Minnesota
Ages
25 Years to 65 Years
Sex
All
Healthy volunteers
No
Enrolment
18 people (planned)
Start
1 December 2026
Primary completion
31 December 2029
Registry last updated
22 September 2026

Sites (2)

  • M Health Fairview DBT Program, Minneapolis, Minnesota, United States
  • M Physicians St. Louis Park Clinic, Saint Louis Park, Minnesota, United States

How joining a trial works

Free to take part
Trials generally cost participants nothing for the study drug and the study visits, and some pay for travel or time. Check what a study covers on its registry page.
Screened first
Every study screens volunteers with questionnaires, medical history and often a physical and psychiatric check. Many people who apply are not enrolled.
Eligibility is strict
Common exclusions include a personal or family history of psychosis or bipolar disorder, some heart conditions, pregnancy and certain medications, which you may be asked to stop under medical supervision. Never stop a medication on your own to qualify.
You may get a placebo
Many trials compare psilocybin with a placebo or a low dose, and you may not be told which you had until the study ends.
Contact the study team through the registry
Each registry record lists the study contacts and sites. We do not republish personal emails or phone numbers; use the link on each trial page.
Not medical advice
This is a list of registry records, not a recommendation. Talk to your doctor before applying. Disclaimer · Safety and medications

Source: ClinicalTrials.gov API v2, U.S. National Library of Medicine, read 28 October 2026. Filter: overall status RECRUITING or NOT_YET_RECRUITING; an intervention named psilocybin, psilocin, COMP360 or CYB003. Refreshed weekly; a study's own registry page is always the current record.

Record read from ClinicalTrials.gov API v2, U.S. National Library of Medicine on 28 October 2026. All psilocybin trials